F
Firefly Bio
Biotech & Life Sciences · South San Francisco, United States · Founded 2022
Unlocking new classes of payloads to maximize the potential of ADCs MoreLess
Firefly Biologics is a venture-backed company based in the Bay Area, currently operating in stealth mode. The company focuses on developing innovative bioconjugate solutions, which are advanced techniques that combine biological molecules with other compounds to enhance their effectiveness in medical treatments. Firefly Biologics aims to revolutionize the field of medicine by realizing the full potential of bioconjugates, making treatments more effective and targeted.
The company primarily serves the biotechnology and pharmaceutical sectors, targeting clients who are looking for cutting-edge solutions to improve their medical products. Operating in the highly competitive and rapidly evolving biotech market, Firefly Biologics leverages its advanced research and development capabilities to stay ahead.
Firefly Biologics' business model revolves around research and development, intellectual property licensing, and strategic partnerships. The company generates revenue through licensing its bioconjugate technologies to pharmaceutical companies and forming partnerships for co-development of new medical treatments. By focusing on innovation and collaboration, Firefly Biologics aims to create significant value for its stakeholders.
Keywords: bioconjugates, biotechnology, pharmaceuticals, medical treatments, innovation, research and development, intellectual property, licensing, strategic partnerships, Bay Area.
Company overview
Firefly Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2022
- Headquarters
- South San Francisco, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 62.4
Valuation & funding
Firefly Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jun 2026 | $1B | $1B | Johnson & Johnson | ↗ |
| SERIES AOther financing | Feb 2024 | $94M | $376M | Eli Lilly · MPM BioImpact · Versant Ventures · Decheng Capital | ↗ |
| SPINOUTOther financing | Jan 2022 | — | — | Stanford University | — |
Growth signals
Firefly Bio website traffic
Latest recorded traffic for Firefly Bio is 1.5K monthly website visits, up 54.6% over the last three months. Firefly Bio's team declined 3.8% over the past year.
Comparisons
Firefly Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Firefly Bio's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Firefly Bio has talent and traffic
team presence
In the news
Latest news about Firefly Bio
Recent press, funding announcements, and product moves mentioning Firefly Bio — open to read from the original sources.
Market sentiment
What the market is saying about Firefly Bio
An AI-synthesized read of the highest-engagement posts about Firefly Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Firefly Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.